Gilead kept at neutral by Merrill

Gilead Sciences Inc. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating. The company is expected to present final data on Monday from a phase 1/2 study of GS-9137, an oral integrase inhibitor for HIV. Top-line GS-9137 data suggested sufficient efficacy and pill size, but Norvir boosting was required. A second-generation integrase inhibitor is likely needed for commercial success. Shares of the Foster City, Calif., biopharmaceutical company were up 68 cents, or 1.12%, at $60.02 on volume of 3,476,644 shares versus the three-month running average of 4,886,680 shares. (Nasdaq: GILD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.